Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. (Q37479213)

20 August 2017

1 reference

title

Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. (English)

1 reference

20 August 2017

0 references

1 reference

John de Groot

1

1 reference

PubMed ID

19436954

20 August 2017

Vanessa Milano

series ordinal

2

1 reference

20 August 2017

13 May 2009

1 reference

Journal of Neuro-Oncology

20 August 2017

1 reference

20 August 2017

95

1 reference

20 August 2017

2

1 reference

20 August 2017

151-163

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-009-9916-2

20 August 2017

0 references

cites work

The 2007 WHO classification of tumours of the central nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

21 January 2018

The hunting of the Src

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Src family kinases in tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Cellular functions regulated by Src family kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

SRC gene expression in human cancer: the role of transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Role of Src expression and activation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Mechanism of biological synergy between cellular Src and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Changing paradigms--an update on the multidisciplinary management of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Chemotherapeutic wafers for High Grade Glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Intravenous carboplatin for recurrent malignant glioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Molecular pathology of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Molecular changes in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Inhibiting kinases in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Combination therapy for malignant glioma based on PTEN status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

PTP alpha regulates integrin-stimulated FAK autophosphorylation and cytoskeletal rearrangement in cell spreading and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Activating SRC mutation in a subset of advanced human colon cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Multiple roles for Src in a PDGF-stimulated cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Activation of extracellular signal-regulated kinase by ultraviolet is mediated through Src-dependent epidermal growth factor receptor phosphorylation. Its implication in an anti-apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

New concepts regarding focal adhesion kinase promotion of cell migration and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

21 January 2018

A renaissance for SRC

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Differential regulation of cell motility and invasion by FAK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

PTEN: life as a tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Yes and PI3K bind CD95 to signal invasion of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Reduced glioma infiltration in Src-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Targeting epidermal growth factor receptor--are we missing the mark?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCdelta, and sphingosine kinase 1 in glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

FAK signaling in anaplastic astrocytoma and glioblastoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Strategies for optimizing combinations of molecularly targeted anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec® ) across the mouse blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-009-9916-2

Src regulates phorbol 12-myristate 13-acetate-activated PKC-induced migration via Cas/Crk/Rac1 signaling pathway in glioblastoma cells.

21 January 2018

1 reference

12 December 2020

Src in cancer: deregulation and consequences for cell behaviour

1 reference

12 December 2020

Platelet-derived-growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: role of pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase

1 reference

12 December 2020

Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma

1 reference

12 December 2020

Epidermal growth factor and insulin-induced deoxyribonucleic acid synthesis in primary rat hepatocytes is phosphatidylinositol 3-kinase dependent and dissociated from protooncogene induction

1 reference

12 December 2020

Fibroblast growth factor receptor-1 regulation of Src family kinases.

1 reference

12 December 2020

Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of hu

1 reference

12 December 2020

Optimizing Outcomes with Maximal Surgical Resection of Malignant Gliomas

1 reference

12 December 2020

Role of Src in signal transduction pathways. The Jubilee Lecture

1 reference

12 December 2020

Gene amplifications associated with the development of hormone-resistant prostate cancer

1 reference

12 December 2020

SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions.

1 reference

12 December 2020

SRC transcriptional activation in a subset of human colon cancer cell lines

1 reference

12 December 2020

Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells

1 reference

12 December 2020

10.1007/S11060-009-9916-2

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19436954